Update on Partnership with 4TEEN4 Pharmaceuticals

Summary by AI BETAClose X

Abingdon Health plc has provided an update on its partnership with 4TEEN4 Pharmaceuticals, confirming its role as the legal manufacturer and CDMO for the DPP3 InvoSelect companion diagnostic test, designed to identify patients who will benefit from 4TEEN4's invobenitug therapy. This collaboration leverages Abingdon Health's expertise in lateral flow development, regulatory strategy, and scaled manufacturing, with a focus on synchronised co-development to align the diagnostic and therapeutic timelines. The project is progressing well, with both companies highlighting the strong collaboration and technical capabilities involved in advancing this potentially life-saving therapy.

Disclaimer*

UK 100

Latest directors dealings